The Anti-Longevity PlaybookGet the Playbook
Evidence Review
Metformin for Longevity
Verdict
PromisingEvidence Tier
B
Moderate evidence
Human Studies
Yes — observational + TAME trial pending
Typical Cost
$4/mo
Metformin shows intriguing observational signals — diabetics on metformin sometimes outlive matched non-diabetic controls. The TAME (Targeting Aging with Metformin) trial is the first FDA-approved aging trial and will provide the first randomized human longevity data. At $4/month, the cost is negligible. The evidence is promising but not yet proven for non-diabetics.
The full evidence review — including the diabetes drug that may outlive every supplement stack — and the trial that will settle the debate — is in Section 2 (Supplements & Compounds) of The Anti-Longevity Playbook.
Reviewed by Dr. Ramy Khalil, MD · Double Board-Certified Internal Medicine · Last updated March 2026
Does metformin slow aging?
Observational data is intriguing — some diabetics on metformin outlive non-diabetic controls. The TAME trial will provide the first randomized longevity data. Promising but not yet proven for non-diabetics.
Free Chapter
Want the full picture?
Start with a free chapter.
Read the first chapter of The Anti-Longevity Playbook free — including the intervention with stronger mortality data than Metformin for Longevity.
More from Supplements & Compounds
Browse All Evidence Reviews
30+ longevity interventions reviewed by a physician against the primary literature.
ExerciseStatinsApoB TestingNMNNMN vs. NR — Which Is Better?ResveratrolRapamycinMetformin for LongevityBPC-157PeptidesCold Plunge / Cold ExposureSaunaSleepTestosterone Replacement TherapyGrowth HormoneContinuous Glucose MonitorFull-Body MRI ScreeningBiological Age TestsSemaglutideTirzepatideIntermittent FastingCaloric RestrictionBerberineOmega-3 Fatty AcidsVitamin DMagnesiumCoQ10SpermidineCreatineSocial ConnectionAlcohol